What Happened?
Palo Alto, CA-based Arixa-Pharmaceuticals Appointed John Freund as Chief Executive Officer
About the Company
Arixa Pharmaceuticals™ is developing oral antibiotics for resistant Gram-negative infections, an urgent need. Our lead program is an oral prodrug of Avibactam®, a broad spectrum beta-lactamase inhibitor recently approved by FDA. We have addressed and solved the medicinal chemistry issues which complicate the prodrugging of this class of compounds, and expect to receive broad composition of matter patent protection.
About the Person
John Freund is Chief Executive Officer at Arixa Pharmaceuticals. Previously, John held various senior HR leadership roles in the industry.
Info Source
News
Short Profile